Related references
Note: Only part of the references are listed.Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
David Neal Franz et al.
LANCET (2013)
Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
D. H. Yoon et al.
BRITISH JOURNAL OF CANCER (2012)
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Jung Hun Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Peter C. Thuss-Patience et al.
EUROPEAN JOURNAL OF CANCER (2011)
Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination
Fumiko Taguchi et al.
INVESTIGATIONAL NEW DRUGS (2011)
Advanced Detection of Recent Changing Trends in Gastric Cancer Survival: Up-to-date Comparison by Period Analysis
Hyo Song Kim et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Okines et al.
ANNALS OF ONCOLOGY (2010)
Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer
Da-zhi Xu et al.
BMC CANCER (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Robert J. Motzer et al.
CANCER (2010)
Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo
Agnes Jaeger-Lansky et al.
CANCER BIOLOGY & THERAPY (2010)
RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase
Kyung-Hun Lee et al.
CANCER LETTERS (2010)
Gastric Cancer Working Group Report
Mitsuru Sasako et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
Toshihiko Doi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer
Guanzhen Yu et al.
CLINICAL CANCER RESEARCH (2009)
Gastric cancer
Vincenzo Catalano et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model
Sven A. Lang et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
AKT phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer
E Oki et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Epidemiology of gastric cancer in Japan
M Inoue et al.
POSTGRADUATE MEDICAL JOURNAL (2005)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
